Making therapeutic sense of antisense oligonucleotides
Researchers from Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, USA, report a modification wherein replacing the RNA strand of a heteroduplex oligonucleotide with DNA may enhance the efficacy of antisense oligonucleotide-based drugs
Tokyo, Japan - Antisense oligonucleotides (ASO) hold great promise for pharmacotherapy. Now, researchers at Tokyo Medical and Dental University (TMDU) and Ionis Pharmaceuticals, advancing their earlier work on a heteroduplex oligonucleotide (HDO) model, have demonstrated augmentation of ASO-based ...
















